Association of Natriuretic Peptides with Cardiovascular Prognosis in Heart Failure with Preserved Ejection Fraction: Secondary Analysis of the TOPCAT Randomized Clinical Trial

JAMA Cardiology

Volumn 3, Issue 10, 2018, Pages 1000-1005

  Myhre, Peder Langeland ^a,b   Vaduganathan, Muthiah ^a   Claggett, Brian L ^a   Anand, Inder S ^c,d   Sweitzer, Nancy K ^e   Fang, James C ^f   O'Meara, Eileen ^g   Shah, Sanjiv J ^h   Desai, Akshay S ^a   Lewis, Eldrin F ^a   Rouleau, Jean ^g   Pitt, Bertram ⁱ   Pfeffer, Marc A ^a   Solomon, Scott D ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b AKERSHUS UNIVERSITY HOSPITAL   (Norway)

^c VETERANS AFFAIRS MEDICAL CENTER   (United States)

^d UNIVERSITY OF MINNESOTA   (United States)

^e UNIVERSITY OF ARIZONA   (United States)

^f UNIVERSITY OF UTAH   (United States)

^g MONTREAL HEART INSTITUTE   (Canada)

^h NORTHWESTERN UNIVERSITY   (United States)

ⁱ UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; BRAIN NATRIURETIC PEPTIDE; BIOLOGICAL MARKER; NATRIURETIC FACTOR;

ADULT; AFRICAN AMERICAN; AGE; AGED; ARTICLE; ATRIAL FIBRILLATION; BODY MASS; CARDIOVASCULAR DISEASE; CLINICAL OUTCOME; CONTROLLED STUDY; DISEASE ASSOCIATION; ESTIMATED GLOMERULAR FILTRATION RATE; ETHNICITY; FEMALE; FOLLOW UP; HEART FAILURE WITH PRESERVED EJECTION FRACTION; HUMAN; KIDNEY FUNCTION; MAJOR CLINICAL STUDY; MALE; MEDICAL HISTORY; MIDDLE AGED; OBESITY; PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROGNOSIS; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; RACE; RANDOMIZED CONTROLLED TRIAL (TOPIC); SECONDARY ANALYSIS; WAIST CIRCUMFERENCE; CLINICAL TRIAL; DOUBLE BLIND PROCEDURE; ETHNOLOGY; HEART FAILURE; HEART STROKE VOLUME; HOSPITALIZATION; METABOLISM; MORTALITY; MULTICENTER STUDY; PATHOPHYSIOLOGY; PHASE 3 CLINICAL TRIAL; RANDOMIZED CONTROLLED TRIAL; RISK ASSESSMENT; RISK FACTOR; SURVIVAL ANALYSIS; VERY ELDERLY;

AGED; AGED, 80 AND OVER; BIOMARKERS; DOUBLE-BLIND METHOD; HEART FAILURE; HOSPITALIZATION; HUMANS; MIDDLE AGED; NATRIURETIC PEPTIDES; PROGNOSIS; RISK ASSESSMENT; RISK FACTORS; STROKE VOLUME; SURVIVAL ANALYSIS;

EID: 85052976069     PISSN: 23806583     EISSN: 23806591     Source Type: Journal    
DOI: 10.1001/jamacardio.2018.2568     Document Type: Article

References (15)

1. Ponikowski P, Voors AA, Anker SD,; ESC Scientific Document Group. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: the Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure of the European Society of Cardiology (ESC) developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur Heart J. 2016; 37 (27): 2129-2200. doi: 10.1093/eurheartj/ehw128 27206819
2. Anand IS, Claggett B, Liu J, Interaction between spironolactone and natriuretic peptides in patients with heart failure and preserved ejection fraction: from the TOPCAT trial. JACC Heart Fail. 2017; 5 (4): 241-252. doi: 10.1016/j.jchf.2016.11.015 28359411
3. Solomon SD, Rizkala AR, Gong J, Angiotensin receptor neprilysin inhibition in heart failure with preserved ejection fraction: rationale and design of the PARAGON-HF trial. JACC Heart Fail. 2017; 5 (7): 471-482. doi: 10.1016/j.jchf.2017.04.013 28662936
4. Chow SL, Maisel AS, Anand I,; American Heart Association Clinical Pharmacology Committee of the Council on Clinical Cardiology; Council on Basic Cardiovascular Sciences; Council on Cardiovascular Disease in the Young; Council on Cardiovascular and Stroke Nursing; Council on Cardiopulmonary, Critical Care, Perioperative and Resuscitation; Council on Epidemiology and Prevention; Council on Functional Genomics and Translational Biology; and Council on Quality of Care and Outcomes Research. Role of biomarkers for the prevention, assessment, and management of heart failure: a scientific statement from the American Heart Association. Circulation. 2017; 135 (22): e1054-e1091. doi: 10.1161/CIR.0000000000000490 28446515
5. Gupta DK, Claggett B, Wells Q, Racial differences in circulating natriuretic peptide levels: the atherosclerosis risk in communities study. J Am Heart Assoc. 2015; 4 (5): e001831. doi: 10.1161/JAHA.115.001831 25999400
6. Pitt B, Pfeffer MA, Assmann SF,; TOPCAT Investigators. Spironolactone for heart failure with preserved ejection fraction. N Engl J Med. 2014; 370 (15): 1383-1392. doi: 10.1056/NEJMoa1313731 24716680
7. Pfeffer MA, Claggett B, Assmann SF, Regional variation in patients and outcomes in the Treatment of Preserved Cardiac Function Heart Failure With an Aldosterone Antagonist (TOPCAT) trial. Circulation. 2015; 131 (1): 34-42. doi: 10.1161/CIRCULATIONAHA.114.013255 25406305
8. Desai AS, Lewis EF, Li R, Rationale and design of the Treatment of Preserved Cardiac Function Heart Failure With an Aldosterone Antagonist Trial: a randomized, controlled study of spironolactone in patients with symptomatic heart failure and preserved ejection fraction. Am Heart J. 2011; 162 (6): 966-972.e910.
9. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). JAMA. 2001; 285 (19): 2486-2497. doi: 10.1001/jama.285.19.2486 11368702
10. Stevens PE, Levin A; Kidney Disease: Improving Global Outcomes Chronic Kidney Disease Guideline Development Work Group Members. Evaluation and management of chronic kidney disease: synopsis of the kidney disease: improving global outcomes 2012 clinical practice guideline. Ann Intern Med. 2013; 158 (11): 825-830. doi: 10.7326/0003-4819-158-11-201306040-00007 23732715
11. Wang TJ, Larson MG, Levy D, Impact of obesity on plasma natriuretic peptide levels. Circulation. 2004; 109 (5): 594-600. doi: 10.1161/01.CIR.0000112582.16683.EA 14769680
12. Anand IS, Rector TS, Cleland JG, Prognostic value of baseline plasma amino-terminal pro-brain natriuretic peptide and its interactions with irbesartan treatment effects in patients with heart failure and preserved ejection fraction: findings from the I-PRESERVE trial. Circ Heart Fail. 2011; 4 (5): 569-577. doi: 10.1161/CIRCHEARTFAILURE.111.962654 21715583
13. Seidelmann SB, Vardeny O, Claggett B, An NPPB promoter polymorphism associated with elevated n-terminal pro-B-type natriuretic peptide and lower blood pressure, hypertension, and mortality. J Am Heart Assoc. 2017; 6 (4): e005257. doi: 10.1161/JAHA.116.005257 28341776
14. Wang TJ, Larson MG, Levy D, Heritability and genetic linkage of plasma natriuretic peptide levels. Circulation. 2003; 108 (1): 13-16. doi: 10.1161/01.CIR.0000081657.83724.A7 12821537
15. Packer M. Epicardial adipose tissue may mediate deleterious effects of obesity and inflammation on the myocardium. J Am Coll Cardiol. 2018; 71 (20): 2360-2372. doi: 10.1016/j.jacc.2018.03.509 29773163